financetom
Business
financetom
/
Business
/
BAT says close to settling Canadian tobacco litigation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BAT says close to settling Canadian tobacco litigation
Oct 18, 2024 12:22 AM

(Reuters) - British American Tobacco ( BTI ) said on Friday a plan has been filed in a Canadian court to potentially resolve and settle its Canadian subsidiary's tobacco litigation in the country, more than five years after the unit filed for bankruptcy protection.

BAT's unit Imperial Tobacco Canada (ITCAN) has been under a court supervised mediation process negotiating a possible settlement of all its outstanding tobacco litigation in Canada.

The unit had sought bankruptcy protection in 2019 shortly after a Quebec court upheld a 2015 decision that awarded smokers in the Canadian province around C$15 billion ($10.88 billion) in a blow to subsidiaries of BAT, Philip Morris International and Japan Tobacco International.

BAT had said it would set aside 436 million pounds ($569.68 million) in 2019, after the Quebec court upheld its decision.

The court-appointed mediator's and monitor's plan of compromise and arrangement has been filed in the Ontario Superior Court of Justice, BAT said on Friday.

"The plan resolves all Canadian tobacco litigation and provides a full and comprehensive release to Imperial, BAT and all related entities for all tobacco claims," ITCAN said in a statement published by BAT.

BAT did not share details of the plan but said the unit was supportive of the settlement framework and structure.

The settlement will be funded by cash on hand and cash generated from the future sale of tobacco products in Canada, the unit said.

($1 = 1.3789 Canadian dollars)

($1 = 0.7653 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Truist Financial's Chief Operating Officer Resigns
Truist Financial's Chief Operating Officer Resigns
Jan 13, 2025
01:01 PM EST, 01/13/2025 (MT Newswires) -- Truist Financial ( TFC ) said Monday that Chief Operating Officer Hugh Cummins III has resigned, effective immediately. Cummins stepped down due to material changes to his responsibilities by Truist following completion of several strategic initiatives, according to a regulatory filing. Truist said Kristin Lesher, chief wholesale banking officer, will take over management...
Update: Market Chatter: Cleveland-Cliffs Teams Up With Nucor in Potential Bid for US Steel
Update: Market Chatter: Cleveland-Cliffs Teams Up With Nucor in Potential Bid for US Steel
Jan 13, 2025
01:07 PM EST, 01/13/2025 (MT Newswires) -- (Updates with Nucor's ( NUE ) response in the fourth paragraph.) Cleveland-Cliffs ( CLF ) is teaming up with Nucor ( NUE ) in a potential bid for US Steel (X), CNBC reported Monday, citing unnamed sources. Cleveland-Cliffs ( CLF ) would buy all of US Steel for cash and then sell the...
Exclusive-Investor climate group suspends activities after BlackRock exit
Exclusive-Investor climate group suspends activities after BlackRock exit
Jan 13, 2025
LONDON/BOSTON (Reuters) - A flagship coalition aimed at aligning the asset management industry with global climate goals said it was suspending its activities on Monday, days after BlackRock ( BLK ), the world's biggest investor, left amid a political backlash in the United States. BlackRock ( BLK ), which manages some $11.5 trillion inassets, left the Net-Zero Asset Managers (NZAM)...
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Jan 13, 2025
01:04 PM EST, 01/13/2025 (MT Newswires) -- Eli Lilly ( LLY ) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved. Shares of Eli...
Copyright 2023-2026 - www.financetom.com All Rights Reserved